Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:20:41.269Z.
Consensus retrieved: 2026-10-06T09:24:41.838Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:20:41.269Z.
Quote observation: 2026-10-06T18:03:36.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c636d25f821ca328dde5756eba65a9b4f657646c0770229dc3782e5e279f5fe4
Forward PE Ratio (N/A) = Dated Quote Price ($0.89) / Consensus Forward EPS ($-268.80)
FORWARD PE RATIO
N/A
Bio Green Med Solution, Inc.
Market Cap
$4.90M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Bio Green Med Solution, Inc. (BGMS) | $4.90M | N/A |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.83M | N/A |
| Xenetic Biosciences, Inc. (XBIO)vs › | $4.81M | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.03M | N/A |
| Imunon, Inc. (IMNN)vs › | $5.08M | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.12M | N/A |
| CalciMedica, Inc. (CALC)vs › | $4.60M | N/A |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.59M | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.21M | N/A |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.23M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $0.89, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-268.80 | $-268.80 – $-268.80 | 1 | n/m |
| 2027-12-31 | $880.80 | $880.80 – $880.80 | 1 | 0.0x |
| 2028-12-31 | $1317.60 | $1317.60 – $1317.60 | 1 | 0.0x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
